[1] 国家心血管病中心. 中国心血管健康与疾病报告编写组. 中国心血管健康与疾病报告2022. 中国循环杂志, 2023.38(6).

[2] Wang, Y, Cao, T, Liu, X. et al. A New Benchmark for Modern Management of Valvular Heart Disease: The Whole-Life Cycle Management System. JACC: Asia. null2025, 0 (0) .

[3] 中国经导管二尖瓣缘对缘修复术临床路径（2022版），中国介入心脏病学杂志，2023，31（3）：161-173.DOI：  10. 3969/j. issn. 1004-8812. 2023. 03. 001

[4] Yang L. Analyses for Prevalence and Outcome of Tricuspid Regurgitation in China: An Echocardiography Study of 134,874 Patients. Cardiology. 2019;142(1):40‐46

[5] 中国医师协会心血管内科医师分会结构性心脏病学组,苏州工业园区东方华夏心血管健康研究院. 三尖瓣反流经导管治疗的中国专家共识[J]. 中国介入心脏病学杂志,2024,32(10). DOI:10.3969/j.issn.1004-8812.2024.10.002.

[6] Zahr F, et al. CLASP IID Randomized Trial and Registry: Two-Year Outcomes of Transcatheter Edge-to-Edge Repair for Degenerative Mitral Regurgitation.  Presented at: TCT Annual Congress; 2024 Oct 30; Washington, DC.

[7] Wild MG, et al. PASTE Investigators. Transcatheter Valve Repair for Tricuspid Regurgitation: 1-Year Results From a Large European Real-World Registry. J Am Coll Cardiol. 2025 Jan 28;85(3):220-231. doi: 10.1016/j.jacc.2024.10.068. Epub 2024 Oct 28. PMID: 39466215.

[8] 注册证编号：国械注进20203130521 产品名称：干式主动脉瓣膜

[9] 注册证编号：国械注进 20243130603 产品名称：干式二尖瓣瓣膜